lysophosphatidic 酸受体 1 抑制:一个潜在的治疗目标为肺纤维化
Elizabeth R Volkmann1, Christopher P Denton2, Martin Kolb3
1Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
概括
向自毒素 (ATX) 和 lysophosphatidic 酸受体 1 (LPAR1) 显示出治疗纤维性疾病如异常性肺纤维化 (IPF) 和全身性硬化症 (SSc) 的前景. 目前正在开发ATX和LPAR1的抑制剂,以满足未满足的医疗需求.
科学领域:
- 药理学 药理学是指药理学的学科.
- 纤维化研究 纤维化研究
- 药物开发 药物开发
背景情况:
- Lysophosphatidic acid (LPA) 和它的受体LPAR1与纤维性疾病的病理学有关,包括IPF和SSc.
- 在IPF和SSc患者中观察到升高的LPA水平,突出显示ATX和LPAR1是关键参与者.
- 目前针对这些纤维状疾病的治疗方法存在局限性,因此需要新的治疗策略.
研究的目的:
- 审查目前关于自毒素 (ATX) 和LPAR1在肺纤维化中的信号传导的文献.
- 为了区分目前正在开发中的新型ATX和LPAR1抑制剂.
- 概述这些新兴治疗剂的作用机制,临床前研究和临床试验.
主要方法:
- 临床前研究和临床试验的文献综述.
- 在纤维化疾病模型中分析ATX和LPAR1信号通路.
- 不同类型的ATX和LPAR1抑制剂的比较.
主要成果:
- ATX和LPAR1的激活有助于炎症和纤维化机制.
- 针对ATX和LPAR1的抑制剂在临床前模型中显示出潜力.
- 几种ATX和LPAR1抑制剂正在进行IPF和SSc的临床试验.
结论:
- 抑制ATX和LPAR1代表了纤维化疾病的有前途的治疗策略.
- 这些向疗法可能会解决IPF,SSc和其他纤维状况的当前护理标准中未得到满足的需求.
- 进一步的研究和临床评估对于确定这些新药的有效性和安全性至关重要.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
144
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
144
01:42Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K